No difference in short-term readmissions following day-case vs. one overnight stay in patients having hip and knee arthroplasty: a nationwide register study of 51,042 procedures from 2010–2020

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 824 KB, PDF-dokument

Background and purpose: Day-case hip and knee arthroplasty has gained in popularity, but there are conflicting results regarding readmissions. We aimed to investigate differences in 30- and 90-day readmission rates between day-case patients and patients with a single overnight stay following primary total hip arthroplasty (THA), total knee arthroplasty (TKA), and unicompartmental knee arthroplasty (UKA).
Patients and methods: We identified day-case (DC) and overnight (ON) THA, TKA, and UKA patients, operated on between 2010 and 2020, from the Danish National Patient Register. Day-case surgery was defined as discharge on the day of surgery. Overnight readmissions within 30 or 90 days of surgery were considered readmissions. We compared readmission rates between DC and ON patients within arthroplasty types using logistic regression adjusted for patient characteristics and year of surgery. We included 29,486 THAs (1,353 DC and 28,133 ON), 15,116 TKAs (617 DC and 14,499 ON), and 6,440 UKAs (1,528 DC and 4,914 ON).
Results: The 30-day readmission rates were: DC-THA 4.4% vs. ON-THA 4.4% (adjusted odds-ratio [aOR] 1.2, 95% confidence interval [CI] 0.91–1.6), DC-TKA 4.7% vs. ON-TKA 4.4% (aOR 1.1, CI 0.69–1.5), and DC-UKA 3.0% vs. ON-UKA 3.0% (aOR 1.1, CI 0.78–1.5). Similarly, no significant differences were present between DC and ON THA, TKA, and UKA regarding 90-day readmissions or time to readmission.
Conclusion: We found no differences in readmission rates between day-case THA, TKA, and UKA patients and patients with a single overnight stay.
OriginalsprogEngelsk
TidsskriftActa Orthopaedica
Vol/bind94
Sider (fra-til)516-522
Antal sider7
ISSN1745-3674
DOI
StatusUdgivet - 2023
Eksternt udgivetJa

Bibliografisk note

Funding Information:
sent was waived. No funding was received specifically for this study. CBJ has received PhD funding from a grant from the Novo Nordisk Foundation unrelated to this study. KG and AT have received research support and speaker fees from Zimmer Biomet, and AT has received research support from Pfizer. NBF has received speaker fees from the Masimo Corporation and Edwards Lifesciences. All the above conflicts are unrelated to this study. Completed disclosure forms for this article following the ICMJE template are available on the article page, doi: 10.2340/17453674.2023.18658

Publisher Copyright:
© 2023 The Author(s).

ID: 396723000